BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca for a rare bone disease market. Alesta is developing a small ...

Amylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes by more than half in ...

Leo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the FDA ...

Slate Medicines is hurtling toward a Nasdaq listing, securing a reverse merger with Fulcrum Therapeutics six months after ...

The Massachusetts research site for Merck KGaA’s North American division, EMD Serono, is handing pink slips to 20 staffers, ...

Antibody platform business OmniAb continues to rack up the Big Pharma partnerships, with Eli Lilly signing off on ...

AstraZeneca has stopped a phase 3 trial of volrustomig in lung | AstraZeneca has stopped a phase 3 trial of volrustomig in ...

Evaxion has scrapped a next-gen solid tumor vaccine in order to channel resources to a candidate specifically targeting brain ...

Lantheus, which recently agreed to an $8 billion takeover by fellow radiopharma Curium, garnered FDA clearance for its Alzheimer’s PET imaging agent, Tauklarify. The clearance for the imaging agent, ...

BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...

Taiho Pharmaceutical and Cullinan Therapeutics have scored a second phase 3 victory for their small molecule EGFR inhibitor, teeing the partners up to challenge Johnson & Johnson for a lung cancer ...

After its last attempt at a merger failed in 2023, Redx Pharma seems to have found a willing partner in Skye Bioscience, which experienced a couple of trial failures in recent years. The public ...